Empliciti (elotuzumab) vs Blenrep (belantamab mafodotin-blmf)
Empliciti (elotuzumab) vs Blenrep (belantamab mafodotin-blmf)
Empliciti (elotuzumab) is an immunostimulatory antibody used in combination with other medications for the treatment of multiple myeloma in patients who have received one to three prior therapies. Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate indicated for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The choice between Empliciti and Blenrep would depend on the individual patient's treatment history, the number of prior therapies, their specific medical condition, and the treating physician's assessment of the potential benefits and risks of each medication.
Difference between Empliciti and Blenrep
Metric | Empliciti (elotuzumab) | Blenrep (belantamab mafodotin-blmf) |
---|---|---|
Generic name | Elotuzumab | Belantamab mafodotin-blmf |
Indications | Multiple myeloma (in combination with lenalidomide and dexamethasone) | Multiple myeloma (for patients who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) |
Mechanism of action | SLAMF7-directed immunostimulatory antibody | BCMA (B-cell maturation antigen)-directed antibody and microtubule inhibitor conjugate |
Brand names | Empliciti | Blenrep |
Administrative route | Intravenous infusion | Intravenous infusion |
Side effects | Fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, pneumonia | Blurred vision, keratopathy, thrombocytopenia, anemia, infusion-related reactions, pyrexia, fatigue, nausea |
Contraindications | None known | Ocular disease, thrombocytopenia, hemorrhage |
Drug class | Monoclonal antibody | Antibody-drug conjugate |
Manufacturer | Bristol-Myers Squibb | GlaxoSmithKline |
Efficacy
Empliciti (Elotuzumab) Efficacy in Multiple Myeloma
Empliciti, also known by its generic name elotuzumab, is a monoclonal antibody used in the treatment of multiple myeloma. It specifically targets a protein called SLAMF7, which is present on the surface of myeloma cells as well as certain immune cells. The efficacy of Empliciti in the treatment of multiple myeloma was demonstrated in clinical trials where it was used in combination with other medications. In a pivotal phase III study known as ELOQUENT-2, patients receiving Empliciti in combination with lenalidomide and dexamethasone showed a significant improvement in progression-free survival compared to those who received only lenalidomide and dexamethasone. This suggests that Empliciti can enhance the therapeutic effects of standard treatment regimens for multiple myeloma.
Blenrep (Belantamab Mafodotin-blmf) Efficacy in Multiple Myeloma
Blenrep, with the generic name belantamab mafodotin-blmf, is another medication approved for the treatment of multiple myeloma. It is an antibody-drug conjugate that combines a monoclonal antibody targeting B-cell maturation antigen (BCMA) with a cytotoxic agent. BCMA is commonly expressed on the surface of multiple myeloma cells. The approval of Blenrep was based on the results of the DREAMM-2 study, a pivotal phase II clinical trial. In this study, patients with relapsed or refractory multiple myeloma who had received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent, were treated with Blenrep. The trial demonstrated a clinically meaningful overall response rate, indicating that Blenrep can provide benefit to patients with heavily pretreated multiple myeloma.
Comparison of Empliciti and Blenrep in Clinical Context
While both Empliciti and Blenrep have shown efficacy in the treatment of multiple myeloma, they are utilized at different stages of the disease and in combination with varying treatment regimens. Empliciti is typically used in combination with lenalidomide and dexamethasone for patients who have received one to three prior therapies. On the other hand, Blenrep is indicated for patients who have received multiple prior lines of therapy and have limited treatment options. The choice between these therapies depends on several factors, including the patient's treatment history, the presence of specific molecular targets on myeloma cells, and the patient's overall health status.
Conclusion
In conclusion, both Empliciti and Blenrep have been shown to be effective treatments for multiple myeloma, albeit in different patient populations and treatment scenarios. Empliciti enhances the efficacy of standard treatment combinations earlier in the treatment course, while Blenrep offers a new option for patients with relapsed or refractory multiple myeloma who have exhausted other therapies. The use of these drugs represents a significant advancement in the management of multiple myeloma, providing hope for improved outcomes in patients suffering from this challenging disease.
Regulatory Agency Approvals
Empliciti
Blenrep
Access Empliciti or Blenrep today
If Empliciti or Blenrep are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us